Hester Biosciences is currently trading at Rs. 445.00, up by 25.00 points or 5.95 % from its previous closing of Rs. 420.00 on the BSE.
The scrip opened at Rs. 425.10 and has touched a high and low of Rs. 455.00 and Rs. 425.00 respectively. So far 3908 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 515.00 on 12-Mar-2015 and a 52 week low of Rs. 85.05 on 18-Mar-2014.
Last one week high and low of the scrip stood at Rs. 515.00 and Rs. 401.10 respectively. The current market cap of the company is Rs. 361.54 crore.
The promoters holding in the company stood at 53.81 % while Institutions and Non-Institutions held 0.31 % and 45.87 % respectively.
Hester Biosciences launched Peste Des Petits Ruminants (PPR) vaccine and Goat Pox vaccine. With the launch of these vaccines as well as being the second largest poultry vaccine manufacturer in India, the company has positioned itself to capitalise on upcoming opportunities in the animal health care industry globally as well as in India.
PPR vaccine is to be given annually to sheep and goats. PPR disease causes dysentery and death of the animal. It is therefore a disease of high economical importance worldwide. The total targeted population of sheep and goat for PPR vaccine in the world is 145 crores. In India, the targeted population is 20 crore.
Hester Biosciences is a 100% biotech company producing animal biological. Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: